.
MergerLinks Header Logo

New Deal


Announced

Completed

Blackstone and CPP Investments completed the acquisition of a majority stake in Advarra from Genstar Capital and Linden Capital for $5bn.

Financials

Edit Data
Transaction Value£4,035m
Consideration TypeCash
Capital Owned-
Capital Bid For-
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

institutional biosafety committee

institutional review board

Medical Services

United States

Majority

Acquisition

Private

Private Equity

Cross Border

Friendly

Completed

Synopsis

Edit

Blackstone, an American multinational private equity, and Canada Pension Plan Investment Board, a global investment management organization, completed the acquisition of a majority stake in Advarra, a provider of regulatory, quality, and compliance solutions and clinical trial technologies, from private equity firms Genstar Capital and Linden Capital, for $5bn. “We are proud to back Advarra given its important role in enabling high-quality clinical R&D and helping its clients bring life-changing treatments to patients. Sustained innovation and scientific advancement in life sciences is one of our highest conviction investment themes across Blackstone. We are excited to partner with Gadi and the rest of the Advarra team to continue investing in talent, differentiated scientific expertise, customer-centric solutions, and innovative clinical trial technology to realize Advarra’s full potential in the years ahead," Anushka Sunder, Blackstone Senior Managing Director.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US